Study 40 of 41NAD+ (Nicotinamide Adenine Dinucleotide) literatureJAMATop journal2026
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
Not reported in abstract.
Where it sits
this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpus18
Preclinical
17
Observational
1
Open-label · this one
1
Randomised
4
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the NAD+ (Nicotinamide Adenine Dinucleotide) corpus
DAn NAD(+)-responsive adipose signal coordinates inter-organ defense against muscle atrophy.Cell metabolism · 2026—CAdipose ILC2s depend on acetyl-CoA carboxylase 1 to maintain metabolic health.Cell metabolism · 2026 · Not reported in abstract.AnimalCLong-term NMN treatment increases lifespan and healthspan in mice in a sex dependent mannerbiorxiv-preprint · 2023 · 8.5% increase in median lifespan in female mice.AnimalCThe mitochondrial deacetylase SIRT3 is nonessential for cyclophilin D-dependent procoagulant platelet formation in mice.Platelets · 2026 · Not reported in abstract.AnimalDA comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.Journal of enzyme inhibition and medicinal chemistry · 2026 · 31 of 46 FDA-approved drugs in 2025 were small molecule drugs.reviewCNicotinamide-derived tumor-targeting carbon dots for Cancer Photothermal therapy.Journal of colloid and interface science · 2026 · Binding energy of NAM-CDs to Ki67 was -7.7 kcal/mol.Animal